KOCAA
SUPN icon

Knights of Columbus Asset Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-69,765
Closed -$1.66M – 418
2019
Q4 		$1.66M Buy
+69,765
New +$1.69M 0.15% 252

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Knights of Columbus Asset Advisors's SUPN Position: Q1 2020 in Review

Knights of Columbus Asset Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 69,765 shares — an estimated $1.66M sold.

Knights of Columbus Asset Advisors first reported a position in SUPN in Q4 2019 and held it in 1 quarter. The position peaked at $1.66M in Q4 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • Knights of Columbus Asset Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 69,765 Supernus Pharmaceuticals shares in Q1 2020, an estimated $1.66M.
  • Knights of Columbus Asset Advisors first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Knights of Columbus Asset Advisors's Supernus Pharmaceuticals position peaked at $1.66M in Q4 2019.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Knights of Columbus Asset Advisors's 13F filing for Q1 2020, filed 15 May 2020.